Document Detail

Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
MedLine Citation:
PMID:  12352328     Owner:  NLM     Status:  MEDLINE    
ACE-inhibitors and AT -receptor antagonists may exert part of their pharmacological actions by interference with angiotensin-and/or bradykinin-mediated prejunctional stimulation of cardiac norepinephrine release. As endogenous formation of angiotensin and bradykinin is increased in ischemia, we investigated the effects of the ACE-inhibitor ramiprilat and the AT -receptor antagonist candesartan on cardiac norepinephrine release in isolated perfused rat hearts, under nonischemic and stop-flow conditions. Exocytotic release of endogenous norepinephrine was induced by electrical field stimulation and measured by HPLC. Paired stimulations were applied in each heart to obtain an intraindividual comparison of the effect of the pharmacological agent on norepinephrine release with the release under baseline conditions. The ACE-inhibitor ramiprilat (0.1-10 nM) and the AT -receptor antagonist candesartan (1-100 nM) were studied during normal flow or in the fourth minute of stop-flow. Under nonischemic conditions, the ACE-inhibitor slightly reduced norepinephrine release at the highest concentration, while the AT -receptor antagonist did not influence norepinephrine release in normoxia. Conversely, both substances significantly increased norepinephrine release during ischemia. Augmentation of norepinephrine release in ischemia by ramiprilat and candesartan was blocked by the bradykinin B -receptor antagonist HOE 140 and, in case of candesartan, by the AT -receptor antagonist PD 123319. The ACE-inhibitor ramiprilat and AT -receptor antagonist candesartan enhance cardiac norepinephrine release selectively in ischemia by stimulating presynaptic bradykinin B -receptors. Regarding the AT -receptor antagonist, AT -receptor activation is also involved in bradykinin-mediated prejunctional stimulation.
Doreen Richardt; Sebastian Wolfrum; Cathy Büttner; Ulrich Schäfer; Andreas Dendorfer; Thomas Kurz; Gert Richardt
Related Documents :
20573508 - Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin...
22052998 - In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterod...
21807018 - Acute blockade of cb1 receptor leads to reinstatement of mdma-induced conditioned place...
21840178 - B(1) and b(2) kinin receptor participation in hyperproliferative and inflammatory skin ...
18348678 - Cysteinyl leukotriene receptor cyslt1 as a novel therapeutic target for allergic rhinit...
23044468 - Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links betwee...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  40     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-09-27     Completed Date:  2003-03-05     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  641-6     Citation Subset:  IM    
Medizinische Klinik II and Institut für experimentelle und klinische Pharmakologie und Toxikologie, Universitätsklinikum Lübeck, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Benzimidazoles / pharmacology*,  therapeutic use
Myocardial Ischemia / drug therapy,  metabolism*
Myocardium / metabolism,  secretion
Norepinephrine / metabolism,  secretion*
Ramipril / analogs & derivatives*,  pharmacology*,  therapeutic use
Rats, Wistar
Receptor, Angiotensin, Type 1
Receptors, Angiotensin / metabolism
Tetrazoles / pharmacology*,  therapeutic use
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzimidazoles; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Angiotensin; 0/Tetrazoles; 51-41-2/Norepinephrine; 6N5U4QFC3G/ramiprilat; 87333-19-5/Ramipril; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lower risk of postinfarct rupture in mouse heart overexpressing beta 2-adrenergic receptors: importa...
Next Document:  Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary o...